These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3143584)

  • 1. Comparative in vitro activity of the two new 4-quinolones S-25930 and S-25932 against gram-positive bacteria isolated from cancer patients.
    Rolston KV; Ho DH; LeBlanc B; Bodey GP
    Eur J Clin Microbiol Infect Dis; 1988 Oct; 7(5):681-3. PubMed ID: 3143584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative in vitro activity of the new difluoro-quinolone temafloxacin (A-62254) against bacterial isolates from cancer patients.
    Rolston KV; Ho DH; LeBlanc B; Gooch G; Bodey GP
    Eur J Clin Microbiol Infect Dis; 1988 Oct; 7(5):684-6. PubMed ID: 3143585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of SCH-34343, a new penam, and other antimicrobial agents against clinical isolates from cancer patients.
    Rolston KV; Alvarez ME; Hoy JF; Alderman HC; Ho DH; Bodey GP
    Chemotherapy; 1986; 32(6):506-14. PubMed ID: 3100147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of fleroxacin (Ro23-6240), a new fluorinated 4-quinolone against isolates from cancer patients.
    Rolston K; Ho DH; LeBlanc B; Bodey GP
    Chemotherapy; 1988; 34(6):448-54. PubMed ID: 3149568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro activity of LY146032 against Staphylococcus aureus, Listeria monocytogenes, Corynebacterium JK, and Bacillus spp., in comparison with various antibiotics.
    Van der Auwera P; Grenier P; Klastersky J
    J Antimicrob Chemother; 1987 Aug; 20(2):209-12. PubMed ID: 2822648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro activity of Sch 34343, a new penam, against gram-positive isolates from cancer patients.
    Rolston KV; Alvarez ME; Hoy JF; Alderman HC; Ho DH; Bodey GP
    J Antimicrob Chemother; 1986 Aug; 18(2):159-62. PubMed ID: 3093447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients.
    Rolston KV; Vaziri I; Frisbee-Hume S; Streeter H; LeBlanc B
    Chemotherapy; 2004 Nov; 50(5):214-20. PubMed ID: 15523180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.
    Hodinka RL; Jack-Wait K; Wannamaker N; Walden TP; Gilligan PH
    Eur J Clin Microbiol; 1987 Feb; 6(1):100-3. PubMed ID: 3032607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro activity of two new quinolone antimicrobial agents, S-25930 and S-25932 compared with that of other agents.
    Neu HC; Chin NX
    J Antimicrob Chemother; 1987 Feb; 19(2):175-85. PubMed ID: 3571042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients.
    Rolston KV; Ho DH; LeBlanc B; Bodey GP
    Antimicrob Agents Chemother; 1987 Jan; 31(1):102-3. PubMed ID: 3471177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro selection of bacteria resistant to the 4-quinolone agents.
    Limb DI; Dabbs DJ; Spencer RC
    J Antimicrob Chemother; 1987 Jan; 19(1):65-71. PubMed ID: 3470281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients.
    Rolston KV; LeBlanc B; Gooch G; Ho DH; Bodey GP
    J Antimicrob Chemother; 1989 Mar; 23(3):363-71. PubMed ID: 2732120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vitro activity of RU 28965, a new macrolide, compared to that of erythromycin.
    Rolston KV; LeBlanc B; Ho DH
    J Antimicrob Chemother; 1986 Feb; 17(2):161-3. PubMed ID: 3700283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of PD127,391, a new quinolone against bacterial isolates from cancer patients.
    Rolston KV; Ho DH; LeBlanc B; Bodey GP
    Chemotherapy; 1990; 36(5):365-72. PubMed ID: 2209169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro activity of PD 117 596, a new quinolone, against bacterial isolates from cancer patients.
    Rolston KV; LeBlanc B; Ho DH; Bodey GP
    J Antimicrob Chemother; 1990 Jul; 26(1):39-44. PubMed ID: 2211445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA; Tayeb OS
    Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative in vitro activity of CI934, a new fluoroquinolone, alone and in combination with coumermycin, against gram-positive bacteria.
    van der Auwera P; Vandermies A; Grenier P; Klastersky J
    Drugs Exp Clin Res; 1987; 13(3):125-32. PubMed ID: 3622241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of difloxacin (A-56619), A-56620, and other 4-quinolones against isolates from cancer patients.
    Rolston KV; Ho DH; LeBlanc B; Bodey GP
    Chemotherapy; 1987; 33(6):419-27. PubMed ID: 3428009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activity of the new erythromycin derivative dirithromycin against gram-positive bacteria isolated from cancer patients.
    Rolston KV; Ho DH; LeBlanc B; Bodey GP
    Eur J Clin Microbiol Infect Dis; 1990 Jan; 9(1):30-3. PubMed ID: 2137413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.